SAHNT Foundation has been building bridges between science and industry. By transferring knowledge and technologies to society and the marketplace, SAHNT Foundation advances the impact of research results on people’s lives around the globe. We have noticed that each individual innovation has specific requirement for regional ecosystem for its growth. SAHNT Foundation facilitates the matchmaking between the technology and the regional ecosystem, and has developed a solid tradition of of collaborating with industry, securing and licensing intellectual property rights, creating spin-off companies and stimulating knowledge-driven regional development. SAHNT Foundation supports researchers throughout the entire knowledge and technology transfer process and helps them to best leverage the societal and economic potential of their research.
SAHNT Foundation helps researchers to protect their intellectual property and devise appropriate strategies for transferring the intellectual property from the university to industry or create spin-off companies: SAHNT Foundation assists researchers during the start-up phase and guides them through the process of translating a business idea into a real company. SAHNT Foundation also provides researchers access to capital funds and other resources such as lab and office space, as well as collaborators around the world.
SAHNT foundation is the world leader in providing constructive solutions to break down existing barriers that refrain patients in medical resource scarce regions from getting adequate medical care. We believe that medical knowledge and technology should be shared by all.
The development of a vaccine to prevent or eradicate H. pylori infection has proven extremely challenging. Attempts to translate the animal model to clinical trial have proven unsuccessful. The majority of early H. pylori vaccine clinical trials focused on the urease antigen with different adjuvants, routes and delivery systems generally proving ineffective in humans. The approach of passive immunization with orally administered antibodies against H. pylori is likely to constitute one of the new therapeutic strategies.
As of 2016, over half of the world’s most important drugs launched after 2008 are not yet approved in China. Several of those included breakthrough treatments of cancer and rare disease. Tens of millions Chinese patients are affected by this delay.
UN Partnership programs
SAHNT foundation is addressing the heath care resource imbalance in China in three areas:
1) Clinical resource imbalance: each physician in the top level hospitals needs to see hundreds of patients per day, and the average duration of every patient-doctor interaction is less than five minutes. 2) Drug development imbalance: New treatment usually have 5-8 years delay to access Chinese market, hence affected tens of millions of Chinese patients. 3) Population Aging related health care imbalance: resource for improve mental health and quality of life of seniors are limited.
SAHNT foundation focuses on education and training of physicians in gatekeeper hospitals in China. we are sponsoring many academic exchange programs, medical education programs, international conference meetings and workshops each year.